We are pleased HLD-0915 has been granted Fast Track designation by FDA for patients with mCRPC,” said Christian Schade, President and CEO of Halda Therapeutics. “Fast Track designation is an important ...

Class 1 carcinogen by the World Health Organization Gastric cancer ranks as the fifth most common cancer globally and the fourth leading cause of cancer-related deaths IRVINE, Calif., Aug. 14, 2025 ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced it will host a webinar on Monday, August 18, 2025, at 8:00 AM ...

Fabio Chianelli Founder, Chairman and CEO PharmaTher Holdings Ltd. About PharmaTher Holdings Ltd. PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on unlocking the pharmaceutical ...

“Tony has a rare track record of turning disruptive science into durable commercial engines,” said Keith Murphy, Executive Chairman, VivoSim Labs. “As sponsors move rapidly to 3D, human-relevant ...

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 ...